Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Ask OQRO reads the filings behind this page and answers in plain words, with a link to each source.
Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Traded Feb 3, 2025 · Filed Feb 5, 2025
Zentalis Pharmaceuticals's PAO and Interim PFO sold $4.5K of Zentalis Pharmaceuticals shares. The filing references tax withholding.
Written from the filing's own figures. OQRO describes what was reported and never tells you what to buy or sell.
open market sale
Code S — open-market or private sale
~$4,476
Shares × reported transaction price
51 days before results of Mar 26, 2025
Results dates are the company's own 8-K (Item 2.02). Many companies only let insiders trade in a window after results
Footnote references tax withholding
Only flagged when a footnote says so; never inferred
Fund moves
From a 13F filed Feb 14, 2025 covering holdings at Dec 31, 2024 — a quarter-end snapshot, not a live trade.
Insider buying
Traded Feb 6, 2025 · filed 6 days later
Zentalis Pharmaceuticals's Chief Medical Officer paid $46K out of pocket for Zentalis Pharmaceuticals shares. 3 other people at Zentalis Pharmaceuticals bought some too, in the same month. Shares held went up 120% with this purchase.
Andrea Paul (Chief Legal Officer) sold ~$23K of Zentalis Pharmaceuticals
Automatic saleEvery dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.